Searchable abstracts of presentations at key conferences in endocrinology

ea0014p409 | (1) | ECE2007

Bone mineral density and bone markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid carcinoma

Mouton F. , D’Herbomez M. , Cao C. Do , Tison-Muchery F. , Marchandise X. , Wemeau J.-L.

Methods: In a prospective longitudinal study, 156 determinations of osteocalcine (OC) as a marker of bone formation, and of C-telopeptide of type-1 collagene (CTX and ICTP) as markers of bone resorption were performed in 103 patients {20 men (median age 50 years), 83 females (median age 56 years – 58% with age >50 years)} treated with suppressive levothyroxine therapy for DTC. Bone mineral density (BMD) of the hip was measured by dual X-ray absorpti...

ea0011p816 | Thyroid | ECE2006

Prognostic factors for persistent or recurrent disease from a series of 81 patients with oncocytic thyroid carcinoma

Do Cao C , Mirghani H , Wemeau JL , Leteurtre E , d’Herbomez M , Marchandise X , Proye C

Much controversy persists over aggressiveness of oncocytic thyroid carcinoma (OTC) and its optimal treatment. The study purpose was to determine prognostic factors for persistent or recurrent disease (PRD) and discuss therapeutic directions.We reviewed the medical records of 81 consecutive patients with OTC among a total of 1729 (4.7%) epithelial thyroid cancers, operated from 1983 to 2003 in our center. Follow-up information was updated. Age ranged from...